Anuh Pharma Ltd

- No additional borrowing is planned currently as the company is managing increased working capital requirements through its own internal resources. - The company has around Rs. 43 crores of short-term loans outstanding, which they intend to repay as they mature. - There is no mention of any immediate plans for equity fundraising. - The company is exploring inorganic expansion through acquisition of a second manufacturing unit but is focused on finding the right candidate before any commitment. - Planned capital expenditure includes about Rs. 4 crores this year to increase manufacturing capacity from 1200 to 1500 metric tons, funded from internal accruals. - Overall, Anuh Pharma is a cash-surplus company and aims to deploy surplus funds either via organic capex or potential acquisition, with no current debt or equity fundraising announced.

- Anuh Pharma plans to undertake a capex of approximately Rs. 4 crore in the current year to increase manufacturing capacity from 1200 metric tons to 1500 metric tons per year. - The company is actively seeking a second manufacturing unit for inorganic growth to diversify and reduce dependency on the current Boisar site. - Investment strategy includes utilizing surplus funds, including cash and liquid assets (approximately Rs. 86 crore), for such expansion when the right acquisition candidate is found. - The company prefers to wait for a suitable strategic acquisition opportunity rather than rushing into inorganic expansion, likening the search to "finding the right bride." - The last major expansion was commissioned in December 2019, involving about Rs. 70 crore of capex funded internally. - Additional capex investments are expected to be somewhat lower than depreciation, keeping fixed assets stable or declining marginally.

- The company targets a top-line growth of around 30% for the current financial year, aiming for approximately ₹485-500 crore in sales revenue. - Domestic and export sales are expected to be nearly balanced, with domestic sales around ₹240 crore and exports about ₹250 crore. - Export demand is currently stronger due to reopening of countries post-COVID. - Volume-wise, capacity utilization is about 65% of 1200 metric tons, with ongoing expansion to increase capacity to 1500 metric tons. - Additional capex of ₹4 crore is planned to support capacity increase. - The company is developing local sourcing for intermediates to ensure steady supply and reduce dependence on China. - They are also exploring inorganic growth through acquisition of a second manufacturing unit. - Two to three new products are planned to be introduced before the end of the year. - Focus remains on bottom-line profitability along with revenue growth.

- Anuh Pharma expects top-line growth of around 30%, targeting approximately Rs. 480-500 crores for the current financial year (April 2021 - March 2022). - Domestic sales are anticipated around Rs. 240 crores, with exports around Rs. 250 crores, with export demand being stronger due to post-COVID country openings. - Bottom-line improvement is a priority over top-line numbers, with significant profit growth observed in recent quarters. - EBITDA margin is expected to improve from the previous year's 12.76%. - The company is focusing on selling higher margin "profit builder" products rather than just volume. - Temporary raw material cost pressures due to China and supply challenges are being addressed by developing local sourcing alternatives. - Capex of Rs. 4 crore underway to increase manufacturing capacity from 1200 to 1500 metric tons, and plans for inorganic expansion are in place. - Overall, the outlook is cautiously optimistic with expected better quarters ahead.

- As of 1st October 2021 (current quarter), the pending order status is reported as good. - Sales of key products like Gliclazide, Ambroxol, Erythromycin, and Sulfadoxine were very good last quarter. - The management expressed confidence in achieving target top line and bottom line for the financial year April 2021 to March 2022. - They are facing some delays and shortages in procurement of certain intermediates from China but are developing alternative local sourcing, expected to complete in two months. - Export market demand is strong in upcoming quarters, supporting optimistic order book outlook. - Domestic market faces price pressures due to DPCO regulations, impacting formulation companies. - Overall, the order book appears steady with good visibility especially on export orders.